Bayer has announced an ambitious plan to launch two groundbreaking drugs this year, each with the potential to generate annual revenues of at least one billion dollars. This strategic move is designed to reinforce the company’s pharmaceutical division amid a backdrop of high debt levels. Known for its robust commitment to healthcare and agricultural products, Bayer’s initiative reflects an adaptive response to evolving global market demands and competitive pressures within the pharmaceutical industry.